[1] Heist RS, Engelman JA. SnapShot: non-small cell lung cancer[J]. Cancer Cell,2012,21(3):448,e2.
[2] Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial[J]. Lancet Oncol.2006 Sep;7(9):719-727.
[3] Zhong WZ, Wang Q, Mao WM, et al.Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage Ⅱ-ⅢA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study[J]. Lancet Oncol,2018,19(1):139-148.
[4] Bang YJ.Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer[J]. J Clin Gastroenterol,2012,46(8):637-648.
[5] Kato H, Arao T, Matsumoto K, et al.Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma[J]. Int J Oncol,2013,42(4):1151-1158.
[6] Ettl T, Stiegler C, Zeitler K, et al.EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis[J]. Hum Pathol,2012,43(6):921-931.
[7] Shi D, He G, Cao S, et al.Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer[J]. Mol Carcinog,1992,5(3):213-218.
[8] Hsieh CC, Chow KC, Fahn HJ, et al.Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung[J]. Ann Thorac Surg,1998,66(4):1159-1163.
[9] Kern JA, Schwartz DA, Nordberg JE, et al.p185neu expression in human lung adenocarcinomas predicts shortened survival[J]. Cancer Res,1990,50(16):5184-5187.
[10] Li BT, Ross DS, Aisner DL, et al.HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers[J]. J Thorac Oncol,2016,11(3):414-419.
[11] Suzawa K, Toyooka S, Sakaguchi M, et al.Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations[J]. Cancer Sci,2016,107(1):45-52.
[12] 李铁英, 李华, 战涛. 不可逆性泛HER抑制剂HM781-36B在埃罗替尼耐药型非小细胞肺癌中的抗肿瘤活性[J]. 安徽医学,2017,38(1):29-32. |
